SecBot SecBot
Biotech Drug Report Generated Nov 12, 2026

IMA402

IMTX·https://immatics.com/
NEUTRAL
Drug Impact Rating4/10
Trial phase
Phase 1b
Time to market
At least 3-5 years away from potential approval, assuming successful completion of Phase 1b dose expansion, a registrational Phase 2/3 trial, and FDA review. No registrational trial has been initiated yet.
Why 4/10
IMA402 is a Phase 1b asset with no upcoming PDUFA or pivotal readout scheduled in the next ~12 months. The most recent catalyst (ESMO 2026 data) has already passed. The next major company catalyst is the SUPRAME Phase 3 readout for anzu-cel (a different asset) in H1 2027. IMA402 is one of several pipeline programs and not the lead asset, so its impact on the stock is moderate.
Actionable Insight NEUTRAL

The next catalyst for IMA402 is continued data maturation from the ongoing Phase 1b dose expansion cohorts, but no specific readout date has been announced. The company's next major binary event is the SUPRAME Phase 3 topline data for anzu-cel (a different asset) expected in H1 2027. IMA402 data will likely be updated at major medical conferences in 2027.

Price Chart

Loading chart...

Executive Summary

IMA402 is a Phase 1b TCR bispecific immunotherapy targeting PRAME, a protein found in over 50 cancer types, developed by Immatics N.V. (NASDAQ: IMTX). Updated data presented at the October 2026 ESMO meeting showed a 32% confirmed objective response rate and 91% 1-year overall survival in advanced melanoma patients with high PRAME expression, along with a favorable safety profile. The drug is still early-stage (Phase 1b dose expansion), with no registrational trial design announced or specific upcoming binary catalyst. Immatics has a strong cash position ($772M as of Q2 2026) and a broad PRAME franchise, but IMA402 is one of several pipeline assets behind the lead program anzu-cel (Phase 3). The stock trades near its 52-week low at $6.69 with analyst consensus Strong Buy and a mean price target of $16.40.

How It Works

IMA402 is a TCR (T cell receptor) bispecific drug, a type of immunotherapy designed to bridge a patient's own T cells (immune cells) to cancer cells that display a protein called PRAME on their surface. PRAME is found in many solid tumor types including melanoma, ovarian, lung and others. By binding both the T cell and the cancer cell simultaneously, IMA402 redirects the immune system to attack and kill PRAME-positive tumor cells. It is engineered with a half-life extension to stay in the body longer between doses.

Trial Status

IMA402 is in an ongoing Phase 1b dose expansion study (NCT05958121) evaluating two dose levels as monotherapy and in combination with immune checkpoint inhibitors, focusing on melanoma and gynecologic cancers. Updated data as of June 1, 2026 cutoff (126 patients treated) was presented at ESMO October 2026. Phase 1a dose escalation previously established a favorable safety profile and clinical proof-of-concept.

The Two-Sided Case

▲ Bull Case6
Updated Phase 1b data at ESMO 2026 showed a 32% confirmed objective response rate and 91% 1-year overall survival in advanced melanoma patients with high PRAME expression, a compelling signal in heavily pretreated patients.
PRAME is expressed in over 50 cancer types, giving IMA402 a broad potential addressable market across multiple solid tumor indications.
The favorable safety profile and ability to combine with checkpoint inhibitors opens a clear development path for both monotherapy and combination regimens.
Immatics has a strong cash position of $772.4M (Q2 2026), funding operations through 2027 and de-risking near-term dilution concerns.
Analyst consensus is Strong Buy (8 Buy, 1 Hold) with a mean price target of $16.40, implying ~144% upside from the current $6.71 price.
Perceptive Advisors made a $7.5M insider purchase at $8.69/share in August 2026, signaling confidence from a major healthcare-focused investor.
▼ Bear Case5
Still early-stage (Phase 1b) with no registrational trial design announced, meaning approval is years away at best.
Competition in TCR bispecifics is intensifying, with Immunocore's approved KIMMTRAK (tebentafusp) and other developers pursuing similar T-cell engager platforms.
Immatics reported a Q3 2026 net loss of $87.5M and revenue of only $8M, burning cash while advancing multiple early-stage programs.
Stock trades near its 52-week low of $6.09, well off the $12.41 high, reflecting market skepticism about valuation and pipeline execution risk.
Several large institutional holders trimmed or exited positions in Q2 2026, including Toronto Dominion Bank (exit) and Millennium Management (trim -51.5%).

Upcoming Catalysts

  • Continued data maturation from Phase 1b dose expansion cohorts (no specific date announced)
  • Potential data presentations at major 2027 medical conferences (ASCO, ESMO)
  • Possible announcement of registrational trial design for IMA402

Source Filing

The SecBot filing or press-release report that triggered this drug report:

https://immatics.com/ PRESS-RELEASE IMTX ·Originating report

Sources · 9

Hover a chip for the title
1 morningstar.com2 kalkinemedia.com3 msn.com4 markets.businessinsider.com5 msn.com6 manilatimes.net7 wpri.com8 ad-hoc-news.de9 seekingalpha.com